MARKET

LCI

LCI

Lannett Co
NYSE

Real-time Quotes | Nasdaq Last Sale

6.17
+0.13
+2.15%
After Hours: 6.15 -0.02 -0.32% 16:00 03/05 EST
OPEN
6.04
PREV CLOSE
6.04
HIGH
6.18
LOW
5.64
VOLUME
668.26K
TURNOVER
--
52 WEEK HIGH
10.70
52 WEEK LOW
4.890
MARKET CAP
255.45M
P/E (TTM)
-1.1855
1D
5D
1M
3M
1Y
5Y
Primidone Market 2021 Predictable to Witness Sustainable Evolution with Bausch Health, Oxford Pharms, Hikma, Amneal
Feb 25, 2021 (Market Insight Reports) -- Stay up-to-date and exploit latest trends of Primidone Market with latest edition released by AMA. Primidone Market...
Market Insight Reports · 02/25 16:03
Thyroid Gland Disorders Treatment Market Size, Share, Industry, Analysis, Price, Trends, Growth, Report and Forecast 2020-2027
Japan, Japan, Thu, 18 Feb 2021 04:28:10 / Comserve Inc. / -- Competitive Analysis: AbbVie Inc., Merck & Co., Inc., Allergan plc, GlaxoSmithKline plc, RLC...
Comserve · 02/19 14:20
Opioids Drugs Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Market Insight Reports · 02/12 10:49
Insider Trends: Lannett Co Insider Extends 90-Day Selling Trend
MT Newswires · 02/10 17:16
Insider Trends: Insider Sales Prolong 90-Day Trend at Lannett Co
MT Newswires · 02/10 17:11
8-K: LANNETT CO INC
(EDGAR Online via COMTEX) -- 0000057725 false 0000057725 2021-02-08 2021-02-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/09 22:08
Pilocarpine Market to Witness Huge Growth by 2026 | Actavis, LGM Pharma, Akorn, Sandoz
Feb 09, 2021 (Market Insight Reports) -- Stay up-to-date and exploit latest trends of Pilocarpine Market with latest edition released by AMA. Pilocarpine...
Market Insight Reports · 02/09 15:30
BRIEF-Lannett Expands Strategic Relationship To Include Biosimilar Fast-Acting Insulin
reuters.com · 02/09 11:54
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LCI. Analyze the recent business situations of Lannett Co through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LCI stock price target is 6.38 with a high estimate of 7.50 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 241
Institutional Holdings: 41.34M
% Owned: 99.85%
Shares Outstanding: 41.40M
TypeInstitutionsShares
Increased
36
1.24M
New
28
-314.21K
Decreased
44
855.88K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.51%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Independent Director
Patrick LePore
Chief Executive Officer/Director
Timothy Crew
Chief Financial Officer/Chief Accounting Officer/Vice President - Finance
John Kozlowski
Chief Operating Officer/Vice President
John Abt
Senior Vice President
Maureen Cavanaugh
Vice President/Chief Information Officer
Robert Ehlinger
General Counsel
Samuel Israel
Director
Jeffrey Farber
Independent Director
John Chapman
Independent Director
David Drabik
Independent Director
Melissa Rewolinski
Independent Director
Paul Taveira
No Data
About LCI
Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company's products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

Webull offers kinds of Lannett Company, Inc. stock information, including NYSE:LCI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LCI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LCI stock methods without spending real money on the virtual paper trading platform.